Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) in Chinese People Aged 18 Years and Over

NCT05364047 is registered in ClinicalTrials.gov with AIM Vaccine Co., Ltd. as lead sponsor.

NCT NCT05364047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05364047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) in Chinese People Aged 18 Years and Over
Lead sponsor
AIM Vaccine Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
July 31, 2021
Completion date
October 31, 2023
Enrollment
144 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19